These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 32217756)

  • 21. Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making.
    Sun D; Xu M; Pan C; Tang H; Wang P; Wu D; Luo H
    Front Oncol; 2022; 12():972972. PubMed ID: 36425562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.
    Wu HX; Wang ZX; Zhao Q; Wang F; Xu RH
    J Immunother Cancer; 2019 Aug; 7(1):206. PubMed ID: 31387639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of tumor mutation burden calculation from gene panel sequencing data.
    Xu Z; Dai J; Wang D; Lu H; Dai H; Ye H; Gu J; Chen S; Huang B
    Onco Targets Ther; 2019; 12():3401-3409. PubMed ID: 31123404
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
    Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
    Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden.
    Chiu TY; Lin RW; Huang CJ; Yeh DW; Wang YC
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34198473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation.
    Li Y; Luo Y
    Sci Rep; 2021 Oct; 11(1):21072. PubMed ID: 34702927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods of measurement for tumor mutational burden in tumor tissue.
    Meléndez B; Van Campenhout C; Rorive S; Remmelink M; Salmon I; D'Haene N
    Transl Lung Cancer Res; 2018 Dec; 7(6):661-667. PubMed ID: 30505710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing.
    Yu Y; Shen L; Ji W; Lu S
    Ann Transl Med; 2021 Jan; 9(2):140. PubMed ID: 33569442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative.
    Esposito Abate R; Pasquale R; Sacco A; Simeon V; Maiello MR; Frezzetti D; Chiodini P; Normanno N
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing.
    Zhou C; Chen S; Xu F; Wei J; Zhou X; Wu Z; Zhao L; Liu J; Guo W
    Ann Transl Med; 2021 Sep; 9(18):1437. PubMed ID: 34733989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement.
    Bailey NG
    Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
    Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
    Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing.
    Anaya J; Sidhom JW; Cummings CA; Baras AS;
    Cancer Res Commun; 2023 Mar; 3(3):501-509. PubMed ID: 36999044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.